We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+10.7%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$680M
AUM Growth
+$44.3M
Cap. Flow
+$13.8M
Cap. Flow %
2.03%
Top 10 Hldgs %
51.48%
Holding
61
New
16
Increased
14
Reduced
12
Closed
11

Top Buys

Rank Stock Value
1
LJPC
La Jolla Pharmaceutical Company
LJPC
+$14.6M
2
NSTG
NanoString Technologies, Inc.
NSTG
+$12.4M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$10.6M
4
XENE icon
Xenon Pharmaceuticals
XENE
+$10.4M
5
XENT
Intersect ENT, Inc
XENT
+$7.03M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$36.9M
2
ENDP
Endo International plc
ENDP
+$24.4M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$17.7M
4
EXAS
Exact Sciences
EXAS
+$15.6M
5
XRAY icon
Dentsply Sirona
XRAY
+$11.5M

Sector Composition

Rank Sector Weight
1 Healthcare 72.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HZNP
26
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$8.04M 1.18%
410,532
-929,043
-69% -$17.7M
SSKN
27
DELISTED
Strata Skin Sciences
SSKN
$7.72M 1.14%
218,136
-76,246
-26% -$1.87M
SRRA
28
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$6.95M 1.02%
102,259
+49,594
+94% +$4.5M
XENT
29
DELISTED
Intersect ENT, Inc
XENT
$6.73M 0.99%
+234,200
New +$7.03M
SLGL icon
30
Sol-Gel Technologies
SLGL
$268M
$6.36M 0.94%
84,770
+20,000
+31% +$1.37M
LIVN icon
31
LivaNova
LIVN
$4.3B
$6.32M 0.93%
51,000
-21,100
-29% -$2.49M
ANGO icon
32
AngioDynamics
ANGO
$562M
$6.28M 0.92%
+289,035
New +$6.42M
QTNT
33
DELISTED
Quotient Limited Ordinary Shares
QTNT
$6.08M 0.89%
20,118
+9,125
+83% +$2.74M
NVLN
34
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$5.77M 0.85%
1,948,554
– –
GBT
35
CALL
DELISTED
Global Blood Therapeutics, Inc.
GBT
$5.7M 0.84%
+150,000
New +$6.64M
ACGN
36
DELISTED
Aceragen Inc
ACGN
$5.61M 0.83%
+37,057
New +$5.29M
ALNY icon
37
Alnylam Pharmaceuticals
ALNY
$36.3B
$5.44M 0.8%
+62,200
New +$6.26M
TSRO
38
CALL
DELISTED
TESARO, Inc.
TSRO
$4.88M 0.72%
125,000
– –
TSRO
39
DELISTED
TESARO, Inc.
TSRO
$4.08M 0.6%
+104,700
New +$3.7M
DXCM icon
40
DexCom
DXCM
$27.6B
$3.46M 0.51%
+96,800
New +$3M
KALA icon
41
KALA BIO
KALA
$11.8M
$3.42M 0.5%
139
-101
-42% -$3.08M
KALV
42
DELISTED
KalVista Pharmaceuticals
KALV
$3.32M 0.49%
+150,000
New +$2.03M
HRTX icon
43
CALL
Heron Therapeutics
HRTX
$86.3M
$3.17M 0.47%
100,000
– –
VRAY
44
DELISTED
ViewRay, Inc.
VRAY
$2.34M 0.34%
+250,000
New +$2.46M
SCYX icon
45
SCYNEXIS
SCYX
$37M
$2.26M 0.33%
23,574
– –
ATEC icon
46
Alphatec Holdings
ATEC
$1.27B
$2.26M 0.33%
669,812
-441,300
-40% -$1.39M
LJPC
47
CALL
DELISTED
La Jolla Pharmaceutical Company
LJPC
$2.01M 0.3%
+100,000
New +$2.61M
VCEL icon
48
Vericel Corp
VCEL
$2.3B
$1.88M 0.28%
+132,600
New +$1.55M
OMED
49
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$424K 0.06%
+200,000
New +$479K
EXAS
50
DELISTED
Exact Sciences
EXAS
– –
-261,400
Closed -$15.6M
1
2
3

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q3 2018 Portfolio in Review

As of Q3 2018, Broadfin Capital held 61 positions worth $680M, up 7% from $635M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Broadfin Capital's Q3 2018 filing shows 16 new, 14 increased, 12 reduced and 11 closed positions. Its largest new stake was NanoString Technologies, Inc.: 850,000 shares worth $15.2M. The largest sale was Mirati Therapeutics, Inc. Common Stock, an estimated $36.9M.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, down from 84% a quarter earlier.

  • Broadfin Capital's largest Q3 2018 buy was NanoString Technologies, Inc.: 850,000 shares worth $15.2M.
  • Broadfin Capital added most to La Jolla Pharmaceutical Company in Q3 2018, an estimated $14.6M increase.
  • Broadfin Capital's biggest Q3 2018 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $36.9M.
  • Broadfin Capital fully exited Endo International plc in Q3 2018, selling an estimated $24.4M.
  • Broadfin Capital's ten largest holdings make up 51% of its $680M portfolio in Q3 2018.
  • Broadfin Capital opened 16 new positions and closed 11 in Q3 2018.
  • Broadfin Capital's portfolio value rose 7% quarter-over-quarter to $680M.

Based on Broadfin Capital's 13F filing for Q3 2018, filed 14 Nov 2018.